pnh treatment: ravulizumab vs. eculizumab
Published 5 years ago • 4.9K plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
1:07
long-term safety and efficacy of eculizumab and ravulizumab in patients with pnh
-
2:30
switching from high-dose eculizumab to weight-based ravulizumab in patients with pnh
-
1:43
the changing treatment landscape of pnh: novel agents and combinations
-
6:40
subcutaneous ravulizumab trial for paroxysmal nocturnal hemoglobinuria treatment
-
1:41
a look at the future treatment landscape of pnh
-
1:51
targeting complement to treat pnh and other hematologic diseases
-
1:29
treating patients with pnh and aa
-
1:19
resolution of hemolysis in a patient with pnh treated with pegcetacoplan
-
1:02:10
introduction of biosimilars on the nhs
-
1:20:17
what is pnh? from diagnosis to treatment 3/23/17
-
10:45
paroxysmal nocturnal hemoglobinuria (heme/onc) - usmle step 1
-
1:51
an overview of the pathophysiology of pnh
-
1:39
new horizons in pnh
-
2:30
international pnh registry: studies, activity & eculizumab efficacy
-
4:25
a potential new treatment for pnh: c3 inhibitor pegcetacoplan reduces markers of hemolysis
-
1:41
thrombosis: a lethal complication in pnh
-
1:30
mosunetuzumab in the treatment of hcl: a case study
-
1:32
pirtobrutinib versus covalent btkis and advice for managing toxicities
-
2:03
the current landscape of treatment for bpdcn
-
3:29
ptcy as gvhd prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction
-
1:02
the challenge of treating bpdcn in a resource-limited setting
-
1:07
key advancements in the treatment of bpdcn from ebmt 2024